Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Double-Blind Placebo-Controlled Study of Orally Administered ATL-104 to Assess Safety, Tolerance and Effect on Oral Mucositis in Patients Following Treatment With Chemotherapy and Peripheral Blood Stem Cell Transplant (PBSCT)

NCT00163280 is registered in ClinicalTrials.gov with Alizyme as lead sponsor.

NCT NCT00163280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00163280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Double-Blind Placebo-Controlled Study of Orally Administered ATL-104 to Assess Safety, Tolerance and Effect on Oral Mucositis in Patients Following Treatment With Chemotherapy and Peripheral Blood Stem Cell Transplant (PBSCT)
Lead sponsor
Alizyme
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2004
Completion date
December 31, 2005
Enrollment
63 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

mucositis